Literature DB >> 20685205

Neurotrophic factor delivery as a protective treatment for glaucoma.

Thomas V Johnson1, Natalie D Bull, Keith R Martin.   

Abstract

Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685205     DOI: 10.1016/j.exer.2010.05.016

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  39 in total

Review 1.  Glaucoma management: relative value and place in therapy of available drug treatments.

Authors:  Deepak Sambhara; Ahmad A Aref
Journal:  Ther Adv Chronic Dis       Date:  2014-01       Impact factor: 5.091

2.  Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies.

Authors:  Natalie D Bull; Thomas V Johnson; Guncha Welsapar; Nicholas W DeKorver; Stanislav I Tomarev; Keith R Martin
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-17       Impact factor: 4.799

Review 3.  Exciting directions in glaucoma.

Authors:  Carol A Rasmussen; Paul L Kaufman
Journal:  Can J Ophthalmol       Date:  2014-12       Impact factor: 1.882

4.  Stem cell therapy for glaucoma: possibilities and practicalities.

Authors:  Thomas V Johnson; Natalie D Bull; Keith R Martin
Journal:  Expert Rev Ophthalmol       Date:  2011-04-01

Review 5.  Genetics of Primary Inherited Disorders of the Optic Nerve: Clinical Applications.

Authors:  Keri F Allen; Eric D Gaier; Janey L Wiggs
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-01       Impact factor: 6.915

6.  SNRPA enhances tumour cell growth in gastric cancer through modulating NGF expression.

Authors:  Ning Dou; Dong Yang; Shijun Yu; Binghao Wu; Yong Gao; Yandong Li
Journal:  Cell Prolif       Date:  2018-07-24       Impact factor: 6.831

Review 7.  Progress of mesenchymal stem cell therapy for neural and retinal diseases.

Authors:  Tsz Kin Ng; Veronica R Fortino; Daniel Pelaez; Herman S Cheung
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results.

Authors:  Umut Arslan; Emin Özmert; Sibel Demirel; Firdevs Örnek; Figen Şermet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-15       Impact factor: 3.117

9.  Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies.

Authors:  Jessica A Cooke; Jason S Meyer
Journal:  Curr Ophthalmol Rep       Date:  2015-08-07

Review 10.  Retinal repair with induced pluripotent stem cells.

Authors:  Shomoukh Al-Shamekh; Jeffrey L Goldberg
Journal:  Transl Res       Date:  2013-11-08       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.